A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study
Titel:
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study
Auteur:
Maio, M. Covre, A. Coral, S. Amato, G. Taverna, P. Lowder, J. Azab, M. Giannarelli, D. Natali, P.G. Di Giacomo, A.M.